File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1002/cam4.70081
- Scopus: eid_2-s2.0-85201051606
- Find via
Supplementary
-
Citations:
- Scopus: 0
- Appears in Collections:
Article: Identification of pyroptosis subtypes and prognosis model of hepatocellular carcinoma based on pyroptosis-related genes
Title | Identification of pyroptosis subtypes and prognosis model of hepatocellular carcinoma based on pyroptosis-related genes |
---|---|
Authors | |
Keywords | hepatocellular carcinoma multiomic analysis prognosis model pyroptosis subtype |
Issue Date | 9-Aug-2024 |
Publisher | Wiley Open Access |
Citation | Cancer Medicine, 2024, v. 13, n. 15 How to Cite? |
Abstract | BackgroundHepatocellular carcinoma (HCC) is a common malignant tumor with poor prognosis. Pyroptosis, a type of programmed cell death, regulates tumor cell development. However, the role of pyroptosis-related genes (PRGs) in HCC and their association with prognosis are unclear. MethodsWe conducted bioinformatics analysis to identify PRGs in The Cancer Genome Atlas-Liver Hepatocellular Carcinoma (TCGA-LIHC) patients. Consensus clustering classified patients into different subtypes. We used LASSO regression to established a pyroptosis subtype-related score (PSRS) related to prognosis. OncoPredict identified potential pharmaceuticals based on PSRS. ResultsWe found 20 HCC-related PRGs in 335 TCGA-LIHC patients. Consensus clustering classified patients into two subtypes. Subtype I had better overall survival and higher response to anti-PD1 treatment. The prognostic model involving 20 genes predicted poorer prognosis for high-PSRS group. The model was validated in two external cohorts. OncoPredict identified 65 potential pharmaceuticals based on PSRS. ConclusionOur investigation revealed a correlation between pyroptosis and HCC. We established PSRS as independent risk factors for predicting prognosis. The study paves the way for using PRGs as prognostic biomarkers and exploring personalized therapy for HCC. |
Persistent Identifier | http://hdl.handle.net/10722/345749 |
ISSN | 2023 Impact Factor: 2.9 2023 SCImago Journal Rankings: 1.174 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Xie, Haisheng | - |
dc.contributor.author | Huang, Guanlin | - |
dc.contributor.author | Mai, Haoming | - |
dc.contributor.author | Chen, Jiaxuan | - |
dc.contributor.author | Na, Rong | - |
dc.contributor.author | Jiang, De-Ke | - |
dc.date.accessioned | 2024-08-27T09:10:55Z | - |
dc.date.available | 2024-08-27T09:10:55Z | - |
dc.date.issued | 2024-08-09 | - |
dc.identifier.citation | Cancer Medicine, 2024, v. 13, n. 15 | - |
dc.identifier.issn | 2045-7634 | - |
dc.identifier.uri | http://hdl.handle.net/10722/345749 | - |
dc.description.abstract | <h3>Background</h3><p>Hepatocellular carcinoma (HCC) is a common malignant tumor with poor prognosis. Pyroptosis, a type of programmed cell death, regulates tumor cell development. However, the role of pyroptosis-related genes (PRGs) in HCC and their association with prognosis are unclear.</p><h3>Methods</h3><p>We conducted bioinformatics analysis to identify PRGs in The Cancer Genome Atlas-Liver Hepatocellular Carcinoma (TCGA-LIHC) patients. Consensus clustering classified patients into different subtypes. We used LASSO regression to established a pyroptosis subtype-related score (PSRS) related to prognosis. OncoPredict identified potential pharmaceuticals based on PSRS.</p><h3>Results</h3><p>We found 20 HCC-related PRGs in 335 TCGA-LIHC patients. Consensus clustering classified patients into two subtypes. Subtype I had better overall survival and higher response to anti-PD1 treatment. The prognostic model involving 20 genes predicted poorer prognosis for high-PSRS group. The model was validated in two external cohorts. OncoPredict identified 65 potential pharmaceuticals based on PSRS.</p><h3>Conclusion</h3><p>Our investigation revealed a correlation between pyroptosis and HCC. We established PSRS as independent risk factors for predicting prognosis. The study paves the way for using PRGs as prognostic biomarkers and exploring personalized therapy for HCC.</p> | - |
dc.language | eng | - |
dc.publisher | Wiley Open Access | - |
dc.relation.ispartof | Cancer Medicine | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | hepatocellular carcinoma | - |
dc.subject | multiomic analysis | - |
dc.subject | prognosis model | - |
dc.subject | pyroptosis subtype | - |
dc.title | Identification of pyroptosis subtypes and prognosis model of hepatocellular carcinoma based on pyroptosis-related genes | - |
dc.type | Article | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.1002/cam4.70081 | - |
dc.identifier.scopus | eid_2-s2.0-85201051606 | - |
dc.identifier.volume | 13 | - |
dc.identifier.issue | 15 | - |
dc.identifier.eissn | 2045-7634 | - |
dc.identifier.issnl | 2045-7634 | - |